Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Stomach Neoplasms 1Solitary Fibrous Tumor, Pleural 1Recurrence 1Ovarian Neoplasms 1Mesothelioma, Malignant 1Gliosarcoma 1Glioma 1Glioblastoma 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Adenocarcinoma 1

Interventions

Cisplatin 5Pemetrexed 4Chemotherapy, Adjuvant 3cediranib 2Radiotherapy 2Neoadjuvant Therapy 2Gemcitabine 2vatalanib 1rilotumumab 1pembrolizumab 1belinostat 1Watchful Waiting 1Vinorelbine 1Sorafenib 1Semaxinib 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Pharmacogenomic Testing 1Methotrexate 1Gefitinib 1Erlotinib Hydrochloride 1Dihematoporphyrin Ether 1Dasatinib 1Capecitabine 1Bevacizumab 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Solitary Fibrous Tumor, Pleural × rilotumumab × Clear all
NCT01105390 2013-08-02

AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma

National Cancer Institute (NCI)

Phase 2 Withdrawn
Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

Data powered by HemOnc (CC BY 4.0) Colophon âš¡